未登录 EphB4-ephrin-B2 are targets in castration resistant prostate cancer Li, Grace Xiuqing; Ma, Binyun; Zhang, Shaobing; Liu, Ren; Siddiqi, Imran N.; Sali, Akash; El-Khoueiry, Anthony; Gross, Mitchell; Salhia, Bodour; Sadeghi, Sarmad; Gill, Parkash S. 分享 收藏
Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC) 新型生物标志物 ephrinB2 (B2) 可预测转移性尿路上皮癌 (mUC) 对治疗的抵抗性以及不良的总生存期 (OS)。 Sadeghi, S.; Mar, N.; Tsao-Wei, D.; Siddiqi, I.; Freeman, D.; Torkko, K.; van Bokhoven, A.; Flaig, T.; Gill, P.; Kalebasty, A. Rezazadeh; Sonpavde, G. P.; Bellmunt, J. 分享 收藏
A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option 一项随机、II期临床试验，旨在评估在局部晚期或转移性移行细胞尿路上皮癌患者中，当顺铂为基础的治疗不可行时，注射用埃罗替尼（eribulin mesylate）联合阿替利珠单抗（atezolizumab）与单独使用阿替利珠单抗（atezolizumab）在安全性及有效性方面的比较。 D'Souza, A. A.; Mar, N.; Parikh, R.; Parikh, M.; Arora, M.; Hinton, S.; Lyou, Y. M.; Ohr, J.; Peracha, S.; Sadeghi, S.; Sulecki, M.; Thomas, R. A.; Villalona-Calero, M.; Lara, P. N.; Sharon, E.; Krailo, M.; Quinn, D. I. 分享 收藏
Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC) Sadeghi, S.; Quinn, D. I.; Dorff, T.; Pal, S. K.; Groshen, S.; Tsao-Wei, D.; Lara, P. N.; Parikh, R.; Devitt, M. E.; Parikh, M.; Jackovich, A.; Vogelzang, N. J.; Burgess, E. F.; Dreicer, R.; Siddiqi, I.; Gill, I.; Gill, P. 分享 收藏
分享 收藏
分享 收藏
Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy Barzi, Afsaneh; Lara Jr, Primo N.; Tsao-Wei, Denice; Yang, Dongyun; Gill, Inderbir S.; Daneshmand, Siamak; Klein, Eric A.; Pinsk, Jacek K.; Penson, David F.; Quinn, David, I; Sadeghi, Sarmad 分享 收藏
EphB4-EphrinB2 receptor-ligand are downstream effectors and novel targets of PTEN deficient prostate cancer Li, Grace X.; Ma, Binyun; Krasnoperov, Valery G.; Siddiqi, Imran; Sali, Akash; Liang, Gangning; Gill, Inderbir S.; Pinski, Jacek K.; Quinn, David I.; Sadeghi, Sarmad; Gill, Parkash S. 分享 收藏
分享 收藏
Phase II California Cancer Consortium trial of gemcitabine-eribulin combination (GE) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): tolerability and toxicity report (NCI-9653; 1UM1CA186717-01, NO1-CM-2011-00038) Sadeghi, S.; Groshen, S.; Parikh, R.; Mortazavi, A.; Dorff, T.; Hoimes, C.; Pal, S.; Levine, E.; Doyle, L.; Quinn, D.; Newman, E.; Lara, P. 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
.png){kind=icon}
分享.png){kind=icon}
收藏